UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 318

Sortiert nach

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Annals of oncology, 2010-02, Vol.21 (2), p.376-381

2010

Volltextzugriff (PDF)

Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death

Journal of clinical oncology, 1999-03, Vol.17 (3), p.1061-1070

1999

Volltextzugriff (PDF)

Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein

Leukemia, 2006-03, Vol.20 (3), p.426-432

2006

Volltextzugriff (PDF)

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

Cancer chemotherapy and pharmacology, 1997-06, Vol.40, p.S13-S19

1997

Volltextzugriff (PDF)

Modulation of multidrug resistance: at the threshold

Journal of clinical oncology, 1993-09, Vol.11 (9), p.1629-1635

Sikic, B I

1993

Volltextzugriff (PDF)

Pharmacologic approaches to reversing multidrug resistance

Seminars in hematology, 1997-10, Vol.34 (4 Suppl 5), p.40

Sikic, B I

1997

Volltextzugriff (PDF)

Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A ) in Patients with Cancer

Clinical cancer research, 1999-11, Vol.5 (11), p.3357-3363

1999

Volltextzugriff (PDF)

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance

Annals of oncology, 2005-12, Vol.16 (12), p.1968-1973

2005

Volltextzugriff (PDF)

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

Journal of clinical oncology, 1992-10, Vol.10 (10), p.1635-1642

1992

Volltextzugriff (PDF)

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance

Journal of clinical oncology, 1994-04, Vol.12 (4), p.835-842

1994

Volltextzugriff (PDF)

Multidrug Resistance (mdrl) Gene Expression in Adult Acute Leukemias: Correlations With Treatment Outcome and In Vitro Drug Sensitivity

Blood, 1991-08, Vol.78 (3), p.586-592

1991

Volltextzugriff (PDF)

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

Journal of clinical oncology, 1992-10, Vol.10 (10), p.1624-1634

1992

Volltextzugriff (PDF)

Pharmacological considerations in the modulation of multidrug resistance

European journal of cancer (1990), 1996-06, Vol.32 (6), p.1082-1088

1996

Volltextzugriff (PDF)

Clinical Studies with Modulators of Multidrug Resistance

Hematology/oncology clinics of North America, 1995-04, Vol.9 (2), p.363-382

1995

Volltextzugriff (PDF)

MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells

British journal of cancer, 2000-10, Vol.83 (7), p.892-898

2000

Volltextzugriff (PDF)

Multidrug resistance in lymphomas

Journal of clinical oncology, 1994-11, Vol.12 (11), p.2453-2459

1994

Volltextzugriff (PDF)

New approaches in cancer treatment

Annals of oncology, 1999, Vol.10, p.149-153

SIKIC, B. I

1999

Volltextzugriff (PDF)

Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia

Leukemia, 2002-05, Vol.16 (5), p.920-927

2002

Volltextzugriff (PDF)

Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations

Cancer, 1993-12, Vol.72 (S11), p.3502-3514

1993

Volltextzugriff (PDF)

Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia

Journal of clinical oncology, 2000-05, Vol.18 (9), p.1867-1875

2000

Volltextzugriff (PDF)

Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells

Molecular pharmacology, 1995-01, Vol.47 (1), p.51-66

1995

Volltextzugriff (PDF)

Integrated genomic analyses of ovarian carcinoma

Nature (London), 2011-06, Vol.474 (7353), p.609-615

2011

Volltextzugriff (PDF)

Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine

Annals of oncology, 1997-06, Vol.8 (6), p.601-603

1997

Volltextzugriff (PDF)

Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection

Cancer research (Chicago, Ill.), 1994-09, Vol.54 (18), p.4980-4987

1994

Volltextzugriff (PDF)

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia an eastern cooperative oncology group pilot study

Cancer, 1999-01, Vol.85 (2), p.358-367

1999

Volltextzugriff (PDF)

1 – 25 von 318

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(271)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(177)
Humans
(174)
Life Sciences & Biomedicine
(169)
Oncology
(110)
Female
(95)
Biological And Medical Sciences
(91)
Medical Sciences
(85)
Male
(73)
Pharmacology. Drug Treatments
(63)
Antineoplastic Agents
(62)
Middle Aged
(52)
Animals
(48)
Adult
(45)
Aged
(42)
General Aspects
(35)
Chemotherapy
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Drug Resistance
(27)
Neoplasms - Drug Therapy
(26)
Mice
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death

Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

Modulation of multidrug resistance: at the threshold

Pharmacologic approaches to reversing multidrug resistance

Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A ) in Patients with Cancer

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance

Multidrug Resistance (mdrl) Gene Expression in Adult Acute Leukemias: Correlations With Treatment Outcome and In Vitro Drug Sensitivity

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

Pharmacological considerations in the modulation of multidrug resistance

Clinical Studies with Modulators of Multidrug Resistance

MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells

Multidrug resistance in lymphomas

New approaches in cancer treatment

Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia

Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations

Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia

Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells

Integrated genomic analyses of ovarian carcinoma

Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine

Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia an eastern cooperative oncology group pilot study

Suchergebnisse filtern